Evidence map›Paper›PMID 32276764›Full record

ArticleGastrointestinal endoscopy2020

A retrospective cohort study of endoscopic therapy and esophagectomy for stage 1 esophageal cancer: less is more.

Justin C McCarty, Robert K Parker, Roberto J Vidri, Kortney A Robinson, Stuart Lipsitz, Sidhu P Gangadharan, Prasad G Iyer

Abstract read
PubMed Publisher
In one paragraph

Article in Gastrointestinal endoscopy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Justin C McCartyHarvard T. H. Chan School of Public Health, Boston, Massachusetts, USA; Center for Surgery and Public Health, Harvard Medical School, Boston, Massachusetts, USA.
Robert K ParkerHarvard T. H. Chan School of Public Health, Boston, Massachusetts, USA; Department of Surgery, Tenwek Hospital, Bomet, Kenya; Department of Surgery, Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Roberto J VidriHarvard T. H. Chan School of Public Health, Boston, Massachusetts, USA; Department of Surgery, St Mary's Regional Medical Center, Lewiston, Maine, USA.
Kortney A RobinsonHarvard T. H. Chan School of Public Health, Boston, Massachusetts, USA; Division of Thoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Stuart LipsitzCenter for Surgery and Public Health, Harvard Medical School, Boston, Massachusetts, USA.
Sidhu P GangadharanDivision of Thoracic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Prasad G IyerDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Harvard University · USBeth Israel Deaconess Medical Center · USMassachusetts Department of Public Health · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsCurrent guidelines recommend consideration of endoscopic therapy (ET) when treating select stage I esophageal cancers. The proportion of esophageal cancers treated with ET compared with esophagectomy has increased over time. Overall and cancer-specific survival have not been shown to be superior with ET in prior population-based studies. We thus evaluated cancer-specific survival comparing patients treated with ET and esophagectomy.

methodsWe performed a retrospective cohort study using the Surveillance, Epidemiology, and End Results database from 2004 to 2015 of patients with node-negative, superficial (T1a/T1b), esophageal cancer treated with ET or esophagectomy. Competing-risks models were used to compare cancer-specific survival. Cox proportional hazards models were used to assess overall survival. Subgroup analysis was performed comparing time periods 2004 to 2009 and 2010 to 2015.

resultsOf 2133 included individuals, 772 (36.2%) underwent ET and 1361 (63.8%) underwent esophagectomy. Unadjusted 5-year survival for cancer-specific death was 87.7% (95% confidence interval [CI], 84.2-90.5) for ET and 82.4% (95% CI, 80.0- 84.5) for esophagectomy (P = .002). Within the adjusted competing-risk model, cancer-specific survival was superior in patients treated with ET compared with esophagectomy (subdistribution hazard ratio [SHR], 1.92; 95% CI, 1.35-2.74; P < .001). From 2004 to 2009, the SHR for esophagectomy was 1.68 (95% CI, 1.07-2.66; P = .024); whereas from 2010 to 2015, the SHR for esophagectomy was 2.02 (95% CI, 1.08-3.76; P = .027).

conclusionsET was associated with improved cancer-specific survival compared with esophagectomy in stage I esophageal cancer. This advantage was more pronounced for patients treated after 2009, potentially because of increasing clinician expertise in performing ET and patient selection.

Indexed as

Esophageal NeoplasmsEsophagectomyEndoscopyEsophagoscopyHumansNeoplasm StagingRetrospective StudiesSurvival RateTreatment Outcome

Identifiers

PMID32276764
OpenAlexW3015541868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.